Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 975-981     DOI: 10.31083/j.rcm2203106
Special Issue: Diet, nutrients and cardiovascular disease prevention
Original Research Previous articles | Next articles
The comparison between the effects of aspirin and clopidogrel monotherapy on postoperative bleeding in diabetic patients after off-pump coronary artery bypass surgery
Levent Altınay1, *(), Erdem Çetin2
1Department of Cardiovascular Surgery, Faculty of Medicine, Bülent Ecevit University, Kozlu, 67000 Zonguldak, Turkey
2Department of Cardiovascular Surgery, Karabük University, Education and Research Hospital, Merkez, 78200 Karabük, Turkey
Download:  PDF(2049KB)  ( 186 ) Full text   ( 13 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
There is limited data about the bleeding complication of antiplatelet therapy after coronary artery bypass graft (CABG) operations focused on diabetic patients. Herein, we aimed to evaluate the effects of aspirin and clopidogrel monotherapies on postoperative bleeding in these patients. A total of 165 diabetic patients who underwent isolated off-pump beating heart coronary artery bypass (OPCAB) operation were evaluated, 84 patients were included in this retrospective study. Patients were divided into groups according to the type of antiplatelet regime. Chest tube drainage amounts and the amount of blood product transfusions were evaluated. Acetylsalicylic acid (ASA) - group included 42 aspirin monotherapy and Clopidogrel - group included 42 clopidogrel monotherapy patients after propensity matching. The mean drainage amount in ASA - group was 670.24 ± 185.46 mL, in Clopidogrel - group was 921.43 ± 167.53 mL (p < 0.001). More packed red blood cell (PRBC) and fresh frozen plasma (FFP) units were needed in the Clopidogrel - group than in the ASA - group (2.05 ± 1.13 vs. 0.83 ± 0.93 units of PRBC, and 1.90 ± 0.58 vs. 1.05 ± 0.58 units of FFP, respectively, p < 0.001). In conclusion, clopidogrel had a stronger effect on bleeding in diabetic patients than aspirin after OPCAB surgery.
Key words:  Coronary artery bypass      Postoperative hemorrhages      Platelet aggregation inhibitors      Diabetes complications      Aspirin      Clopidogrel     
Submitted:  04 May 2021      Revised:  05 July 2021      Accepted:  21 July 2021      Published:  24 September 2021     
*Corresponding Author(s):  Levent Altınay     E-mail:  laltinay@gmail.com

Cite this article: 

Levent Altınay, Erdem Çetin. The comparison between the effects of aspirin and clopidogrel monotherapy on postoperative bleeding in diabetic patients after off-pump coronary artery bypass surgery. Reviews in Cardiovascular Medicine, 2021, 22(3): 975-981.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203106     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/975

[1] Nicholas C. Sanderson, William A. E. Parker, Robert F. Storey. Ticagrelor: clinical development and future potential[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 373-394.
[2] Yao-Yao Han, Zheng-Xiang Li, Rong Duan. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 167-174.
[3] Carmelo Dominici, Massimo Chello. Impact of human immunodeficiency virus (HIV) infection in patients undergoing cardiac surgery: a systematic review[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 411-418.
[4] Sean-Xavier Neath, John L. Jefferies, Jeffrey S. Berger, Alan H.B. Wu, Joseph P. McConnell, Jeffrey L. Boone, Peter A. McCullough, Robert L. Jesse, Alan S. Maisel. The Current and Future Landscape of Urinary Thromboxane Testing to Evaluate Atherothrombotic Risk[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 119-130.
[5] Udaya S. Tantry, Paul A. Gurbel. Current Options in Oral Antiplatelet Strategies During Percutaneous Coronary Interventions[J]. Reviews in Cardiovascular Medicine, 2011, 12(S1): 4-13.
[6] Luca Fileti, Gianluca Campo, Marco Valgimigli. Latest Clinical Data on Testing for High On-Treatment Platelet Reactivity[J]. Reviews in Cardiovascular Medicine, 2011, 12(S1): 14-22.
[7] Tom A. Lassar, Daniel I. Simon, Kevin Croce. Optimizing Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical Pathways for Platelet Function Testing[J]. Reviews in Cardiovascular Medicine, 2011, 12(S1): 23-33.
[8] Ehtisham Mahmud, Lawrence Ang. Platelet Function Testing in Practice: A Case Study[J]. Reviews in Cardiovascular Medicine, 2011, 12(S1): 34-39.
[9] Michael S. Lee, Jenna Nguyen. Treatment Options for Patients With Left Main Coronary Artery Disease[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 77-83.
[10] Matthew J. Price, Udaya S. Tantry, Paul A. Gurbel. The Influence of CYP2C19 Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Clinical Effectiveness of P2Y12 Inhibitors[J]. Reviews in Cardiovascular Medicine, 2011, 12(1): 1-12.
[11] Amit P. Amin, David J. Cohen. Cost-Effectiveness of Alternative Approaches to the Management of Chronic Obstructive Coronary Artery Disease[J]. Reviews in Cardiovascular Medicine, 2009, 10(S2): 3-13.
[12] Stanley Chou, Shervin Eshaghian, Amanda Lamer, Hai Tran, Suhail Dohad, Sanjay Kaul. Bridging Therapy in the Perioperative Management of Patients With Drug-Eluting Stents[J]. Reviews in Cardiovascular Medicine, 2009, 10(4): 209-218.
[13] Gregg C. Fonarow. Best of the ACC 2009 Scientific Session[J]. Reviews in Cardiovascular Medicine, 2009, 10(2): 110-120.
[14] Norman E. Lepor, Michael A. Weber. Best of the ESC Congress 2008[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 261-268.
[15] Jason Kahn, Gregg W. Stone, Martin B. Leon, Caitlin E. Cox, Kim Dalton, Kiersten Feil, Gary S. Mintz. TCT 2008: New Data Lead to New Directions in Treating Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 269-274.
No Suggested Reading articles found!